Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.
Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli MA, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio MR, Marra M, Caraglia M, Tonini G. Santini D, et al. Among authors: berruti a. Oncol Rep. 2011 Jun;25(6):1545-8. doi: 10.3892/or.2011.1235. Epub 2011 Mar 28. Oncol Rep. 2011. PMID: 21455582 Free article.
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.
Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Mancarella S, De Lena M, Alquati P, Dogliotti L. Berruti A, et al. J Clin Oncol. 2000 Oct 1;18(19):3370-7. doi: 10.1200/JCO.2000.18.19.3370. J Clin Oncol. 2000. PMID: 11013277 Clinical Trial.
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A. Sperone P, et al. Among authors: berruti a. Endocr Relat Cancer. 2010 Apr 21;17(2):445-53. doi: 10.1677/ERC-09-0281. Print 2010 Jun. Endocr Relat Cancer. 2010. PMID: 20410174 Clinical Trial.
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.
Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G. Santini D, et al. Among authors: berruti a. J Cell Physiol. 2011 Mar;226(3):780-4. doi: 10.1002/jcp.22402. J Cell Physiol. 2011. PMID: 20857484
Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G, Angeli A, Bertetto O. Fusco V, et al. Among authors: berruti a. J Clin Oncol. 2011 Jun 10;29(17):e521-2; author reply e523-4. doi: 10.1200/JCO.2011.35.1551. Epub 2011 May 2. J Clin Oncol. 2011. PMID: 21537047 No abstract available.
Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy).
Fusco V, Galassi C, Berruti A, Ortega C, Ciuffreda L, Scoletta M, Goia F, Migliario M, Baraldi A, Boccadoro M, Loidoris A, Bertetto O. Fusco V, et al. Among authors: berruti a. ISRN Oncol. 2013;2013:672027. doi: 10.1155/2013/672027. Epub 2013 Feb 27. ISRN Oncol. 2013. PMID: 23533811 Free PMC article.
530 results